KRTX News and Press, Karuna Therapeutics Inc. From 09/01/21

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will participate in a fireside chat at the 20...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairm...

Karuna Therapeutics (NASDAQ:KRTX): Q2 GAAP EPS of -$1.17 beats by $0.12. The Company ended the quarter with $543.6 million in cash, cash equivalents and available-for-sale investment securities compared to $322.3 million as of December 31, 2020. Press Release For further details see: Ka...

All Phase 3 trials in the EMERGENT clinical program evaluating KarXT for the treatment of psychosis in adults with schizophrenia are enrolling Topline data from the Phase 3 EMERGENT-2 trial expected mid-2022 On track to initiate the Phase 3 ARISE trial evaluating KarXT...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Steve Paul, M.D., chief executive officer, president and chairm...

Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...

Hazal Ak/iStock via Getty Images Gelesis, makers of the weight loss pill Plenity, is going public through a reverse merger with SPAC Capstar Special Purpose Acquisition Corp. ([[CPSRU]] -0.6%). The deal is expected to give Gelesis an equity value of about $1.3B, and give the company gross pro...

Combination therapy with patent protection through 2039. Sufficiently funded for cash run through 2023. Upcoming catalyst by the end of the year. For further details see: Karuna Therapeutics: Clear Path To NDA

Karuna Therapeutics (KRTX) announces data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT (xanomeline-trospium) in healthy elderly volunteers.The Company had previously announced a preliminary analysis from the first two cohorts in the trial earlier this year...

Company to initiate a Phase 2 trial evaluating KarXT in dementia-related psychosis in the first half of 2022 Results suggest that KarXT can be administered to elderly volunteers at doses which achieve xanomeline blood levels similar to those reported in the Phase 2 EMERGENT-1 ...